BioPharma Dynamics has expanded its portfolio for the cell and gene therapy market to offer a range of chemically defined t-cell media, DMSO-free cryopreservation solutions, and recombinant growth factors.
Suitable for cell therapy applications at any stage, the portfolio of cell media products include immune cell media, stem cell media, and cell cryopreservation solutions. Supporting applications which require the expansion or differentiation of mesenchymal stem cells and mesenchymal stromal cells, or expansion or cultivation of t-cells.
With a strong company focus of providing complete solutions to their customers, BioPharma Dynamics already offer extensive complimentary products to this media range through cell culture processing and storage solutions. Including bottles, sampling systems and specialised cell culture processing bags which are gas permeable and can be custom manufactured in any shape or size to suit the exact application needs.
Whilst in applications where safe freezing of biologics is required, the advanced cryopreservation solutions can be matched with a range of cryopreservation bags and overwraps to preserve cells without compromising functionality.
The ability to be able to choose the correct product for a specific step in cell processing is important to end users, providing flexibility whilst ensuring sterility, BioPharma Dynamics have a variety of solutions available that can be further customised to suit each application.
With an established relationship in supplying to the UK’s growing cell and gene therapy industry, the Salford-based life sciences company endeavours to further their offering to the cell and gene therapy space as it continues to grow at an exponential rate.
BioPharma Dynamics provides media solutions for cell and gene therapy
The company already offers extensive complimentary products to this media range through cell culture processing and storage solutions
You may also like
Trending Articles
You may also like
Manufacturing
Moderna invests $140m to onshore drug product manufacturing and complete US end-to-end mRNA network
Moderna is expanding its Norwood, Massachusetts site to bring drug product manufacturing in-house, creating hundreds of biomanufacturing jobs and establishing full domestic, end-to-end production for its mRNA vaccines and therapeutics by 2027
Manufacturing
GEA to showcase Rockwell Automation-Compatible GEA kytero 2000 Single-Use Separator at Automation Fair 2025
As a gold-level OEM member of the Rockwell PartnerNetwork™, GEA is strengthening its collaboration with Rockwell by offering full compatibility between the kytero® 2000 and Rockwell’s latest hardware and software suite